Literature DB >> 20068349

Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C.

Motohisa Akiyama1, Tatuki Ichikawa, Hisamitsu Miyaaki, Yasuhide Motoyoshi, Shigeyuki Takeshita, Eisuke Ozawa, Satoshi Miuma, Hidetaka Shibata, Naota Taura, Kazuhiko Nakao.   

Abstract

BACKGROUND/AIM: The frequency of regulatory T cells (Tregs) may be related to persistent hepatitis C virus (HCV) infection. We studied the alteration of the Treg ratio in peripheral blood mononuclear cells (PBMCs) from chronic hepatitis C patients during combination therapy compared with the Treg ratio in liver-infiltrating lymphocytes (LILs) before therapy.
METHOD: The study group consisted of 20 patients who were treatment-naive and had high virus titers of HCV genotype 1. Blood samples were collected prior to treatment and at several time points during treatment. All patients received a liver biopsy prior to treatment. Forkhead box P3 (Foxp3)+, CD3+, CD4+ and CD8+ cells in PBMCs and LILs were stained by specific antibodies.
RESULTS: Ten patients had a sustained virological response (SVR), and 10 patients were non-responders. The SVR group had a significant increase in the Foxp3+/CD4+ ratio in PBMCs at 8 and 12 weeks as well as a significant decrease in the Foxp3+/CD4+ ratio and increase in the CD8+/Foxp3+ ratio in LILs.
CONCLUSION: The evaluation of Tregs, a potentially significant factor for persistent HCV infection, in LILs prior to treatment and in PBMCs during treatment could predict the result of combination therapy. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068349     DOI: 10.1159/000274976

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  6 in total

1.  Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

Authors:  Tatsuya Kanto; Michiyo Inoue; Tsugiko Oze; Masanori Miyazaki; Mitsuru Sakakibara; Naruyasu Kakita; Tokuhiro Matsubara; Koyo Higashitani; Hideki Hagiwara; Sadaharu Iio; Kazuhiro Katayama; Eiji Mita; Akinori Kasahara; Naoki Hiramatsu; Tetsuo Takehara; Norio Hayashi
Journal:  J Gastroenterol       Date:  2011-09-27       Impact factor: 7.527

2.  Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C.

Authors:  Chunqiu Hao; Yun Zhou; Yu He; Chao Fan; Li Sun; Xin Wei; Linxu Wang; Meijuan Peng; Pingzhong Wang; Jianqi Lian; Zhansheng Jia
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

3.  Treatment with IP-10 induces host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice.

Authors:  Gaurav Gupta; Saikat Majumdar; Anupam Adhikari; Parna Bhattacharya; Asok Kumar Mukherjee; Suchandra Bhattacharyya Majumdar; Subrata Majumdar
Journal:  Med Microbiol Immunol       Date:  2011-05-01       Impact factor: 3.402

4.  Antigen-Pulsed CpG-ODN-Activated Dendritic Cells Induce Host-Protective Immune Response by Regulating the T Regulatory Cell Functioning in Leishmania donovani-Infected Mice: Critical Role of CXCL10.

Authors:  Saikat Majumder; Amrita Bhattacharjee; Bidisha Paul Chowdhury; Suchandra Bhattacharyya Majumdar; Subrata Majumdar
Journal:  Front Immunol       Date:  2014-06-04       Impact factor: 7.561

5.  Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C.

Authors:  Bettina Langhans; Hans Dieter Nischalke; Simone Arndt; Ingrid Braunschweiger; Jacob Nattermann; Tilman Sauerbruch; Ulrich Spengler
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

6.  CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation.

Authors:  Stenard Fabien; Morales Olivier; Ghazal Khaldoun; Viallon Vivian; Aoudjehane Lynda; Ouaguia Laurissa; Goormachtigh Gautier; Calmus Yvon; Delhem Nadira; Conti Filomena
Journal:  Biomed Res Int       Date:  2014-01-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.